Yun Bin Lee

Has grant

Associate Professor

Seoul National University Hospital
Country flagSouth Korea

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

The National Research Foundation of Korea (NRF) grant

Open Date: 2015-11-01

Close Date: 2018-10-01

Grant: Close

Grant of the Research Driven Hospital R&D project,

Open Date: 2015-11-01

Close Date: 2018-10-01

Articles (20)

Supplementary Figure S4. Kaplan–Meier estimates of time to progression and overall survival according to etiology in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2025

Supplementary Figure S2. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2025

Supplementary Figure S1. Kaplan–Meier estimates of time to progression and overall survival in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2025

Supplementary Figure S3. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2025

Supplementary Figure S5. Kaplan–Meier estimates of time to progression and overall survival according to etiology in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2025

Purpose: Synergistic effect of radiotherapy and immunotherapy for the treatment of hepatocellular carcinoma (HCC) has been reported. This phase I/IIa pilot trial evaluated preliminary efficacy and safety of combination of radioembolization with yttrium-90 microspheres (Y90-radioembolization) and durvalumab in patients with locally advanced unresectable HCC. Patients and Methods: Patients with Child-Pugh score ≤ 7 and locally advanced HCC, defined as Barcelona Clinic Liver Cancer (BCLC) stage B HCC or BCLC-C disease without extrahepatic metastases, received Y90-radioembolization followed by intravenous durvalumab 1,500 mg 7 to 14 days after Y90-radioembolization and every 4 weeks thereafter. Primary endpoint was time to progression (TTP) assessed by modified RECIST (mRECIST). Secondary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) determined by mRECIST, and safety. Results: All 24 patients enrolled received Y90-radioembolization and 23 received at least one dose of durvalumab. Median follow-up duration was 19.0 months (range, 2.2–24.2). Median TTP was 15.2 months [95% confidence interval (CI), 6.1–not estimated]. Median OS was not reached and 18-month OS rate was 58.3% (95% CI, 36.4–75.0). Median PFS was 6.9 months (95% CI, 5.4–15.2). Seven (29.2%) patients had a complete response and 13 (54.2%) had a partial response; ORR was 83.3% (95% CI, 62.6–95.3). Eleven (47.8%) patients experienced any-grade treatment-related adverse events. Two (8.7%) patients had grade 3 treatment-related adverse events (neutropenia and fever). None experienced any treatment-related serious adverse events. Conclusions: In patients with locally advanced unresectable HCC, the combination of Y90-radioembolization and durvalumab demonstrated promising efficacy and safety, warranting further evaluation in large-scale controlled trials.

Year:

2025

Supplementary Figure S3. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2024

Supplementary Figure S1. Kaplan–Meier estimates of time to progression and overall survival in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2024

Supplementary Figure S4. Kaplan–Meier estimates of time to progression and overall survival according to etiology in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2024

Supplementary Figure S2. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Eun Ju Cho

Seoul National University

SOUTH KOREA
View details

Hyo-Cheol Kim

Clinical Professor

Seoul National University Hospital

SOUTH KOREA
View details

Yoon Jun Kim

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Jin Chun Paeng

Associate Professor

Seoul National University Hospital

SOUTH KOREA
View details

Jung‐Hwan Yoon

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Jeong-Hoon Lee

Professor

Seoul National University Hospital

SOUTH KOREA
View details